Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at Exosomes and Circulating Biomarkers 2013 Summit

SAN DIEGO - September 5, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Company Chairman and CEO, Jim Joyce has accepted an invitation to present at the Exosomes and Circulating Biomarkers 2013 Summit on September 12th. Mr. Joyce's presentation is entitled; "Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer." The presentation will highlight the clinical advancement of the Aethlon Hemopurifier® in treating hepatitis c virus (HCV) and discuss the opportunity to expand therapeutic indications to include cancer based on targeting the elimination of circulating tumor-secreted exosomes. The conference will be held at the Town and Country Resort Hotel in San Diego, California.

Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). Under the IDE, Aethlon will enroll ten end stage renal disease (ESRD) patients infected with HCV as part of a feasibility study to demonstrate Hemopurifier safety. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and other disease conditions.
The conference abstract of the presentation follows:
Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer on 9/12/13 at 3:45pm pacific.
The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Medical Technology Research Alert: Zacks Small Cap Research Update for Aethlon Medical (OTCQB:AEMD); "Remain Encouraged By Ongoing Progress"

Point Roberts, WA, New York, NY - August 20, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a research alert for Aethlon Medical, Inc. (OTCQB: AEMD). Yesterday Brian Marckx, CFA from Zacks Small Cap Research issued an update on the company entitled, “Remain Encouraged By Ongoing Progress”.

Excerpt from Zacks Small Cap Research, Brian Marckx, CFA:
Aethlon Medical (OTC BB:AEMD) filed their 10-Q for the fiscal first quarter ending 6/30/2013 on August 13th. Revenue came in in-line with our number with operating income coming in much better than our estimate as a result of AEMD doing a nice job of cutting operating expenses and conserving resources. AEMD booked $196k in DARPA contract revenue in Q1 which was in-line with our number. Revenue relates to the twelfth milestone under the DARPA contract (the fourth milestone under the year-2 contract). Subsequent to the end of fiscal Q1 AEMD invoiced for and was paid another $404k which relates to the thirteenth and fourteenth milestones.
AEMD also disclosed in the 10-Q that they have submitted to Battelle their first invoice for work the company is doing under the previously announced subcontract agreement that the company has with Battelle related to the $22.8 million systems integrator contract with DARPA. AEMD's initial invoice is for just over $20k which we assume will be recorded and collected in fiscal Q2. As a reminder, AEMD's subcontract is a time and materials contract so the total that AEMD will eventually bill will not be known until their work is completed. We do, however, think it's likely that there will be additional revenue contribution from this contract throughout the year.
FullZacks Small Cap Research news :
http://finance.yahoo.com/news/aemd-remain-encouraged-ongoing-progress-110000029.html
3 month chart:
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitterhttp://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights.  Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 or 212-822-8842 Source - www.Investorideas.com

Technical Breakout; Aethlon Medical (OTCQB: AEMD) Sets Record Trading Highs

Point Roberts, WA, New York, NY - August 7, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a technical trading alert for Aethlon Medical, Inc. (OTCQB: AEMD). The stock had a technical breakout and a significant 5 day run. Following breaking through its 52 week high of $.020, it traded up over 40% in yesterdays session to close at $0.27 on strong volume and momentum.

On July 18 th Zacks Small Cap Research issued an update entitled AEMD: Recent Progress Helps De-Risk Aethlon by Brian Marckx, CFA. The report included a pricing target for the stock that has since been surpassed.
Investors have reacted to a stream of positive news in the past several weeks including
FDA approval of an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
Additionally the company announced a contract from the Defense Advanced Research Projects Agency, or DARPA, including partners Battelle, NxStage Medical (NASDAQ: NXTM), that represents a four year $22.83 million deal to design, develop, test and validate an advanced, portable medical device.
The most recent update was an announcement that the European Patent Office has provided Aethlon with a Decision to Grant a Patent entitled "METHOD OF REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS” has taken the stock to a new technical trading pattern.
The European Patent will be assigned Patent No. 1624784 and has been referenced in European Patent Office Bulletin No. 13/29.
August 6 th close
5 day chart
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Zacks research link:
http://finance.yahoo.com/news/aemd-recent-progress-helps-risk-110000781.html
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter   http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 or 212-822-8842Source - www.Investorideas.com

Stem Cell Stock Alert: BioRestorative Therapies (OTCBB: BRTX) Receives Approval to Conduct Retrospective Safety Study on its Bulging/ Herniated Disc Procedure

JUPITER, Fla. - August 6, 2013 (Investorideas.com Newswire) BioRestorative Therapies Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has received approval from the Western Institutional Review Board ("the Board") to complete a retrospective safety study on selected subjects previously treated by the Company's brtxDISC™ bulging and herniated disc procedure. The study is titled "Re-consenting and Follow-Up of Adults from a Retrospective Study Using Autologous Transplantation of Marrow Derived Mesenchymal Stem Cells to Degenerated Intervertebral Disc."

Study objectives are to determine the safety of subjects who received transplants of their own stem cells into their disc, using MRI and Quality of Life Questionnaires. The Board requires that all subjects must be able to consent for themselves to be enrolled in the study, which has been approved to take place at the Centeno-Schultz Clinic in Broomfield, Colorado.
The approval allows BRT to retrospectively collect and analyze clinical data on selected subjects who previously have been treated for bulging or herniated disc disease with the Company's novel brtxDISC™ procedure. These procedures were performed using BRT's proprietary therapeutic delivery device cannula system and its proprietary culture method isolating a selective population of mesenchymal stem cells. BRT expects to complete the study within a six-month period.
"This is a significant milestone in taking our brtxDISC™ procedure closer towards an FDA meeting to seek approval for the commencement of our clinical trial. We look forward to collecting this data with the ambition of meeting the safety requirements necessary for us to receive approval and start our trial," commented Mark Weinreb, Chief Executive Officer of BioRestorative Therapies. "Our goal is to compile and present the necessary data to the FDA with the goal of initiating a Phase I or Phase II clinical trial in the early part of next year."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

• brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
• ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
• brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.
This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth
ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BioRestorative has compensated Investoridea for a six month news program ( five thousand ) to be published on Investorideas.com newswire and syndication and social media partners.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Trades at 52-Week High

Point Roberts, WA, New York, NY - August 6, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a trading alert for Aethlon Medical, Inc. (OTCQB: AEMD). The stock closed Monday’s trading session at $0.1870, gaining 0.0270 or 16.88% on over 1.9 Million shares. The stock traded as high as $0.20, its 52- week high.

The stock made its first run in July when it announced FDA approval of an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
The next move was after news that Battelle, NxStage Medical (NASDAQ: NXTM), Inc. and Aethlon Medical (OTCQB: AEMD) won a contract from the Defense Advanced Research Projects Agency, or DARPA. The contract funded in phases and could be as large as $22.83 million and last as long as four years -- is for leading one of DARPA's DLT System Integration projects. The project calls for Battelle and key subcontractors, NxStage and Aethlon, to design, develop, test and validate an advanced, portable medical device that exhibits the technical innovation for which DARPA projects are known, and to coordinate integration of key technologies developed during the overall DLT program. This funding does not include human clinical trials that may be required prior to military use and/or United States Food and Drug Administration clearance for sepsis-treatment technologies.
Reaching these key milestones followed by news that that the European Patent Office has provided the Company with a Decision to Grant a Patent entitled "METHOD OF REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS” has taken the stock to a new technical trading pattern.
The European Patent will be assigned Patent No. 1624784 and has been referenced in European Patent Office Bulletin No. 13/29.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 or 212-822-8842
Source - www.Investorideas.com

Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Gains 21%

Point Roberts, WA, New York, NY - August 2, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a trading alert for Aethlon Medical, Inc. (OTCQB: AEMD), The stock is trading at 0.17, up 0.03 or 21.43% as of 2:25PM EDT on over 1.3 Million shares, with a high of $0.18.

In late July the company reported that Battelle, NxStage Medical (NASDAQ: NXTM), Inc. and Aethlon Medical (OTCQB: AEMD) won a contract from the Defense Advanced Research Projects Agency, or DARPA, to develop an innovative, new medical device that may save the lives of soldiers -- and civilians as well -- by treating sepsis.
The contract, funded in phases and could be as large as $22.83 million and last as long as four years -- is for leading one of DARPA's DLT System Integration projects. The project calls for Battelle and key subcontractors, NxStage and Aethlon, to design, develop, test and validate an advanced, portable medical device that exhibits the technical innovation for which DARPA projects are known, and to coordinate integration of key technologies developed during the overall DLT program. This funding does not include human clinical trials that may be required prior to military use and/or United States Food and Drug Administration clearance for sepsis-treatment technologies.
The company also reported in July FDA approval of an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease conditions.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 or 212-822-8842
Source - www.Investorideas.com

Stem Cell Stock Alert: BioRestorative Therapies (OTCBB: BRTX) Provides Company Updates with Shareholder Letter

JUPITER, Fla. - August 1, 2013 (Investorideas.com Newswire) BioRestorative Therapies Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on stem cell-based therapeutics, today announced the issuance of a shareholder letter by Chief Executive Officer, Mark Weinreb, providing an update to shareholders on the Company's progress.

The shareholders were advised as follows:
Over the past 12 months, BRT's substantial investment in research and development has allowed the Company to continue executing on its growth strategy. There have been many developments, both operationally and scientifically, that have positioned the Company well as a growing stem cell biotechnology company with a specific focus on cellular treatments and therapies for certain medical applications.
Below are some of the Company's accomplishments and activities over the past 12 months:

• In the latter part of 2012, BRT appointed Wayne A. Marasco, M.D., Ph.D. as Chairman of its Scientific Advisory Board. Dr. Marasco currently serves as an Associate Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. He is head of Marasco Labs, an accomplished research laboratory at Dana-Farber Cancer Institute known for discovery and therapeutic human monoclonal antibody development and for constructing and validating various human-mouse chimeric models in the area of cancer, infectious disease immunotherapy, regenerative medicine and tissue engineering. Dr. Marasco is a Principal Faculty Member of the Harvard Stem Cell Institute and has extensive experience in the field of stem cells.
• Late last year, the Company announced that its common stock had begun trading on the OTC Bulletin Board. The company went through a very thorough and diligent review process by FINRA to attain the Bulletin Board listing. The Bulletin Board trading platform allows for more potential investors interested in purchasing the Company's stock. The Company is extremely pleased to provide investors increased visibility and transparency that this regulated quotation service provides.
• In late November, BRT launched its new website available at www.biorestorative.com. The new site highlights the Company as an innovator and pioneer in the adult stem cell industry. The Company's primary programs are highlighted in more detail on the website, along with rich imagery and information about therapies being developed.
• At the start of 2013, the Company was invited to present at the Adipose Tissue Biology conference of the Keystone Symposia conference series. Chief Scientist and Vice President of Research and Development, Francisco Silva, presented the Company's research on "Human Metabolically Active Brown Adipose Tissue Derived Stem Cells." This research is a result of the scientific work the Company has been performing pursuant to its ThermoStem® Program, which is in the pre-clinical stage and which focuses on treatments for metabolic disorders (particularly focusing on Type 2 diabetes) and obesity and uses adult derived stem cells from brown adipose (fat) tissue stem cells.
• On April 13th, Dr. Marasco spoke at the Second International Vatican Adult Stem Cell Conference: Regenerative Medicine -- A Fundamental Shift in Science and Culture. The event was held in Vatican City from April 11th to April 13th. Dr. Marasco spoke during the session entitled "Stem Cells, Cancer and Aging — A Search for Solutions." His talk was titled "What Questions Haven't Been Addressed with Respect to Stem Cells, Cancer and Aging?"
• In April, the Company was invited to present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria. Mr. Silva presented the Company's research on Human Metabolically Active Brown Adipose Tissue Derived Stem Cells. This research is a result of the scientific work the Company has been performing pursuant to its ThermoStem® Program.
• The Company hired ProActive Capital in mid-April to help increase awareness of the Company among the investment community. ProActive Capital is also helping to increase exposure through the use of social and digital media.
• In mid April, the Company implemented a 1-for-50 reverse stock split which reduced its outstanding shares from 820,641,011 to 16,412,820. 94% of the shares voted were in favor of the proposal. The Company believes the reverse split will help attract a new base of shareholders as well as new institutional and retail support in the market.
• In mid May, the Company signed an agreement with Dexterity, Inc., a product design and bioengineering firm, to further the development and production of its brtxDISC™ (Disc Implanted Stem Cells) stem cell therapy device. This device plays an integral role in delivering stem cells for its proprietary bulging/herniated disc therapy.
• In May, the Company once again presented its investment thesis at the Marcum MicroCap Conference. To listen to the webcast, please visit http://wsw.com/webcast/marcum/brtx. The event hosted nearly 100 publicly traded companies with capitalizations under $500 million and attracted more than 1,000 people, including senior personnel from the presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace.
• At the end of May, the Company formally launched its "brtx-C Cosmetic" Program. The Company announced that it has developed a human cellular-derived extract that, per initial in vitro studies, when applied to skin cells, appears to cause a significant increase in collagen and fibronectin production (proteins that are essential for combating the aging of skin). The Company plans to conduct additional in vitro studies to better understand the extract's mechanism of action and human cellular activity and is actively seeking collaborations with other parties to commercialize the product.
• In mid June, financial personality and founder of NBT Equities Research, Tobin Smith, interviewed CEO Mark Weinreb with regard to the Company's hybrid business model and what it is currently doing that will help change the biotechnology landscape. Click here for the full interview: http://direct.nbtequitiesresearch.com/video/nbt-biorestorative-1
• In late June, the Company expanded its ThermoStem® Program by collecting 150 samples of human brown adipose tissue. This strengthens its R & D platform for the development of treatments for metabolic disorders and obesity. For the past year, through strategic collaboration and internal efforts, the Company has grown a large library of human brown fat stem cells. The compilation of a large number and variety of brown fat derived stem cells allows it to study and identify potential cell lines to be used in developing therapies.
• In mid July, the Company was featured in the industry publication, "The Life Sciences Report." In the interview included in the report, CEO Mark Weinreb described how the Company's cell therapy process could possibly keep disc disease treatment out of the operating theater. Link to full interview: http://www.thelifesciencesreport.com/pub/na/15470
• Since 2011, the Company has raised approximately $9 million, which has enabled it to achieve clear milestones as it continues to build momentum on its growth strategy.

"Based on these accomplishments, we are excited for what lies ahead in the near and long term," states CEO Mark Weinreb. "We continue to make speedy and efficient progress with our programs and look forward to further advancements regarding each of our exciting initiatives. I would like to thank all of our shareholders for their continued support. We will continue to work diligently to further execute our growth plan so that BioRestorative Therapies will be able to mature into a prominent life sciences company."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

• brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
• ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
• brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.
This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth
ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BioRestorative has compensated Investoridea for a six month news program ( five thousand ) to be published on Investorideas.com newswire and syndication and social media partners.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894